Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

  Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...

April 03, 2024 | Wednesday | News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte and China Medical System Holdings Limited  are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...

April 02, 2024 | Tuesday | News
AstraZeneca Set to Acquire Amolyt Pharma in a Deal Worth Up to $1.05 Billion

The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...

March 14, 2024 | Thursday | News
Kenai Therapeutics Secures $82 Million Series A Funding to Advance Parkinson's Disease Treatment Trials

  – Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...

March 11, 2024 | Monday | News
Dyadic International, Inc. Teams Up with Israel Institute for Biological Research to Combat Emerging Diseases and Bio-Threats

Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a prominent global biotechnology company specializing in advanced microbial platform...

February 21, 2024 | Wednesday | News
Almirall S.A. Partners with Novo Nordisk to Develop Novel Dermatological Therapy

  "This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pa...

February 20, 2024 | Tuesday | News
Sarepta's ELEVIDYS Supplement Accepted by FDA for Duchenne Treatment Expansion

ChatGPT CAMBRIDGE, Mass.--(BUSINESS WIRE)--February 16, 2024 07:00 AM Eastern Standard Time Sarepta Therapeutics, Inc. (NASDAQ:...

February 19, 2024 | Monday | News
Ultragenyx Completes Dosing in Stage 1 of UX701 Gene Therapy Trial for Wilson Disease

Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of ...

January 26, 2024 | Friday | News
Seegene Teams Up with Microsoft for a Disease-Free World Vision

Strategic collaboration to open a new chapter in the field of molecular diagnostics that aspires to 'a world free from all diseases and future pandemics'...

January 24, 2024 | Wednesday | News
DNAnexus and TMA Precision Health Collaborate to Enhance Rare Disease Diagnostics and Treatments

-DNAnexus, Inc., the provider of the Precision Health Data Cloud, and TMA Precision Health, a global health platform for rare diseases, announced a collabo...

January 24, 2024 | Wednesday | News
Andelyn Biosciences and Armatus Bio Collaborate on AAV Gene Therapy for Rare Neurological Disease CMT1A

As part of the agreement, Armatus will leverage Andelyn’s extensive experience in adeno-associated virus (AAV) production and its proprietary suspens...

January 17, 2024 | Wednesday | News
JCR and Alexion Partner on Oligonucleotide Therapeutics Using J-Brain Cargo® Technology

-JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida: “JCR”) announces that it has signed a Research Collaboration, Op...

December 22, 2023 | Friday | News
First patient in China has been dosed in the YOLT-201 clinical trial for the treatment of Hereditary ATTR-CM

The study by YolTech is a single-arm, open-label, dose-escalation clinical trial ( NCT06082050). This trial's primary objectives are to ...

December 18, 2023 | Monday | News
CHMP Greenlights Biogen's SKYCLARYS® for Rare Neurodegenerative Disease

Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1 Milestone highlights Biogen’s growing portfolio in...

December 18, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in